ReviewFrontiers in oncology2021
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Individualized pharmacotherapy: background and development.Annals of translational medicine · 2026Review
- HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.Cancer metastasis reviews · 2026Review
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.Nature reviews. Clinical oncology · 2026Review
- FDA 2025 Cancer Drug Approvals: targeted therapy dominates.Exploration of targeted anti-tumor therapy · 2026Article
- Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence.Journal of pathology informatics · 2025Article
- Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nature reviews. Immunology · 2025Article
- HER2 testing: evolution and update for a companion diagnostic assay.Nature reviews. Clinical oncology · 2025Review
- Oncogenic gene fusions in cancer: from biology to therapy.Signal transduction and targeted therapy · 2025Review
- Bridging Gaps in Oncology: Comparative Analysis of Development and Approval Pathways for Anticancer Drugs and Companion Diagnostic in the United States and Japan.Clinical and translational science · 2025Article
- Twenty-five years with HER2 targeted therapy.Annals of translational medicine · 2024Review
- Mapping the ethical landscape of digital biomarkers: A scoping review.PLOS digital health · 2024Article
- Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.Journal of personalized medicine · 2024Review
- Article
- Mass Spectrometric ITEM-ONE and ITEM-TWO Analyses Confirm and Refine an Assembled Epitope of an Anti-Pertuzumab Affimer.Biomolecules · 2023Article
- HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.Journal for immunotherapy of cancer · 2023Article
- Review
- Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.Methods in molecular biology (Clifton, N.J.) · 2023Article
- HER2/positive and HER2/low in inflammatory breast cancer recurrence.Journal of medicine and life · 2022Article
- Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.Virchows Archiv : an international journal of pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of trastuzumab (Herceptin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.